Compare Payoneer Global Inc (PAYO) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Payoneer Global Inc vs Repligen Corporation Common Stock — how do they compare? Payoneer Global Inc trades at $7.13 (market cap $2.42B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 4.6× Payoneer Global Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, Repligen Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Payoneer Global Inc for 62 Days and Repligen Corporation Common Stock for 0 Days on average.
| PAYO | RGEN | |
|---|---|---|
Market Cap | $2.42B | $11.14B |
Volume | 1,032,721 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $7.18 | $194.57 |
52-Week Low | $4.27 | $102.87 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $2.16B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Payoneer Global (PAYO) trades at $7.14, up 0.28% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. Fundamentally, the company reported Q2 2026 earnings of $0.02 per share, missing estimates, but revenue grew 10% excluding interest. Recent news highlights the renewal of its partnership with Etsy through 2029 and an agreement to be acquired by Nuvei, announced on June 15, 2026.
The outlook is shaped by the pending acquisition, which offers a potential exit for shareholders, but execution risks and recent earnings misses pose concerns. Analyst sentiment is positive with a 60% buy rating, yet investors should weigh acquisition certainty against operational performance volatility and competitive pressures in the fintech sector.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
